Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2909 - Prognostic value of FGFR1 overexpression and amplification in esophageal squamous cell carcinoma patients: a combined analysis from TCGA database


08 Oct 2016


Poster Display


Baoqing Chen


Annals of Oncology (2016) 27 (6): 522-525. 10.1093/annonc/mdw391


B. Chen, S. Liu, J. Wang, B. Hu, H. Xu, R. Tong, X. Hu, J. Xue, Y. Lu

Author affiliations

  • Department Of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University,, 610041 - Chengdu/CN


Abstract 2909


To explore the clinical and prognostic value of fibroblast growth factor receptor 1 (FGFR1) mRNA expression and amplification in patients with esophageal squamous cell carcinoma (ESCC).


FGFR1 mRNA expression was measured by quantitative RT-PCR in tumor tissue of 145 Chinese patients with ESCC who underwent surgery during January 2009 and December 2010 in West China Hospital. Pooled data about FGFR1 mRNA expression, amplification and survival of 186 patients with Esophageal Carcinoma was extracted from TCGA database (TCGA, Provisional). Log rank and Cox proportional hazards regression were conducted to analyze the correlation between survival and FGFR1 mRNA expression or amplification.


Univariate analysis showed ESCC patients with higher FGFR1 mRNA expression had significantly shorter overall survival (OS: 22.00 vs 33.00 months; P =0.038) than those with lower FGFR1 mRNA expression. Multivariate modeling confirmed that patients with higher FGFR1 mRNA expression had a significantly greater risk of death than those with lower FGFR1 mRNA expression after adjusting for pathologic stage (hazard ratio [HR]= 1.54, 95 % confidence interval [CI] = 1.03–2.30, P = 0.037). However, the analysis of pooled data from TCGA indicates there is no significant association between FGFR1 mRNA expression and OS in ESCC patients (25.10 vs 25.07 months; P =0.477). Either in our local or TCGA data sets, no significantly correlation between FGFR1 mRNA expression and disease free survival (DFS) was found (21.10 vs 39.00 months, P =0.1413; 18.10 vs 21.22 months; P =0.334). Pooled analysis of TCGA datasets showed FGFR1 amplification was found in 13/186 (6.98 %) of all patients and was more frequent but without significant difference in squamous cell carcinoma than that in adenocarcinoma (10.31 % vs 3.37 %; P = 0.064). Survival analysis showed ESCC with FGFR1 amplification had no significantly difference in OS (25.47 v 35.80 months; P =0.499) than those without FGFR1 amplification.


Our analyses results support FGFR1 mRNA expression but not amplification could be an independent prognostic biomarker in patients with surgically resected ESCC.

Clinical trial identification

not applicable

Legal entity responsible for the study

Jianxin Xue


West China Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings